Genome & Company (KOSDAQ:314130)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,370.00
+85.00 (2.59%)
At close: Sep 9, 2026

Genome & Company Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-41,361-6,428-20,112-47,466-51,838-34,117
Depreciation & Amortization
6,0206,6727,4478,2729,4622,591
Loss (Gain) From Sale of Assets
-5,97976.8979.5177.11-0.6912.93
Asset Writedown & Restructuring Costs
3,0953,0958,3672,325--
Loss (Gain) From Sale of Investments
1,248583.4-40.28-46.44--
Stock-Based Compensation
3,3213,1552,34212,0666,0835,566
Provision & Write-off of Bad Debts
-----12.92-
Other Operating Activities
16,618-23,431-8,964-4,648-3,864-1,658
Change in Accounts Receivable
-475.24153.34-459.041,126-1,14511.95
Change in Inventory
-3,086-308.83-1,898-1,694-886.4-154.36
Change in Accounts Payable
5.3140.2988.24132.77-139.7914.8
Change in Other Net Operating Assets
3,043-1,995-3,182-2,368-1,2091,573
Operating Cash Flow
-17,550-18,387-16,331-32,224-43,550-26,159
Operating Cash Flow Growth
------

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-540.08-284.66-3,970-18,853-6,849-2,875
Sale of Property, Plant & Equipment
----0.960.5
Cash Acquisitions
-9,770-----26,721
Sale (Purchase) of Intangibles
-112.36-151.18-216.34-189.09-427.29-504.78
Investment in Securities
2,346-7,52815,8494,7427,453-29,609
Other Investing Activities
-15.1470.62-112.66-1,129-99.49-100.48
Investing Cash Flow
-8,092-7,49411,551-15,43077.52-59,810

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-142.225,83032,509--
Long-Term Debt Repaid
--20,908-568.03-2,023-1,645-820.29
Net Debt Issued (Repaid)
11,454-20,7665,26230,487-1,645-820.29
Issuance of Common Stock
7,670-33.8481.49126.831,248
Repurchase of Common Stock
-26,988-54,155----
Other Financing Activities
9,97227,023-49.78-35.6157.69
Financing Cash Flow
30,830-22,1735,24630,56878,55017,617

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
2,203-1,8978,7271,2261,089453.3
Miscellaneous Cash Flow Adjustments
-0-00-00-0
Net Cash Flow
7,391-49,9509,192-15,86036,167-67,898

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-18,090-18,671-20,301-51,077-50,399-29,034
Free Cash Flow Growth
------
Free Cash Flow Margin
-73.95%-75.94%-73.17%-357.28%-357.83%-6434.20%
Free Cash Flow Per Share
-515.84-596.33-666.18-1808.70-1790.39-1080.03
Levered Free Cash Flow
-14,286-21,481-17,433-31,442-35,323-17,129
Unlevered Free Cash Flow
-11,671-18,531-15,220-30,355-35,213-17,095

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
582.73596.87587.12310.78170.852.71
Cash Income Tax Paid
-41.2170.9592.9254.3110.84
Change in Working Capital
-512.49-2,110-5,451-2,804-3,3791,446